Cargando…

Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals

Although radiolabeled alpha-melanocyte stimulating hormone-analogue NAPamide derivatives are valuable melanoma-specific diagnostic probes, their rapid elimination kinetics and high renal uptake may preclude them from being used in clinical settings. We aimed at improving the pharmacokinetics of radi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szücs, Dániel, Szabó, Judit P., Arató, Viktória, Gyuricza, Barbara, Szikra, Dezső, Tóth, Imre, Képes, Zita, Trencsényi, György, Fekete, Anikó
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536547/ https://www.ncbi.nlm.nih.gov/pubmed/37765089 http://dx.doi.org/10.3390/ph16091280

Ejemplares similares

The Synthesis and Preclinical Investigation of Lactosamine-Based Radiopharmaceuticals for the Detection of Galectin-3-Expressing Melanoma Cells
por: Gyuricza, Barbara, et al.
Publicado: (2022)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

Methods for the Determination of Transition Metal Impurities in Cyclotron-Produced Radiometals
por: Forgács, Viktória, et al.
Publicado: (2022)

Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
por: Gyuricza, Barbara, et al.
Publicado: (2021)

Synthesis of (68)Ga-Labeled cNGR-Based Glycopeptides and In Vivo Evaluation by PET Imaging
por: Gyuricza, Barbara, et al.
Publicado: (2021)

Synthesis, Physicochemical, Labeling and In Vivo Characterization of (44)Sc-Labeled DO3AM-NI as a Hypoxia-Sensitive PET Probe
por: Szücs, Dániel, et al.
Publicado: (2022)

PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [(68)Ga]Ga-NODAGA-AMBA and [(44)Sc]Sc-NODAGA-AMBA
por: Kálmán-Szabó, Ibolya, et al.
Publicado: (2022)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review
por: Trencsényi, György, et al.
Publicado: (2023)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
por: Rusckowski, Mary, et al.
Publicado: (2016)

Impact of radiopharmaceutical therapy ((177)Lu, (225)Ac) microdistribution in a cancer-associated fibroblasts model
por: Tranel, Jonathan, et al.
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
por: Desy, Alessandro, et al.
Publicado: (2022)

Radiolysis-Associated Decrease in Radiochemical Purity of (177)Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process
por: Larenkov, Anton, et al.
Publicado: (2023)

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical
por: Mercanoglu, Guldem, et al.
Publicado: (2023)

Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics
por: Képes, Zita, et al.
Publicado: (2023)

Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis
por: Trencsényi, György, et al.
Publicado: (2023)

A New Oxygen Containing Pyclen-Type Ligand as a Manganese(II) Binder for MRI and (52)Mn PET Applications: Equilibrium, Kinetic, Relaxometric, Structural and Radiochemical Studies
por: Csupász, Tibor, et al.
Publicado: (2022)

Accuracy of two dosimetry software programs for (177)Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
por: Ramonaheng, Keamogetswe, et al.
Publicado: (2022)

Implant Imaging: Perspectives of Nuclear Imaging in Implant, Biomaterial, and Stem Cell Research
por: Polyak, Andras, et al.
Publicado: (2023)

Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies
por: Trencsényi, György, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

R205/206 at intersection I2, ISR
Publicado: (1974)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Development of (177)Lu-phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_opv77mcdsf6bhbqbs0250moa71